NCT00053144View on ClinicalTrials.gov

Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

November 30, 1999

Primary Completion Date

February 28, 2003

Study Completion Date

March 31, 2003

Conditions
Leukemia
Interventions
DRUG

cytarabine

DRUG

irinotecan hydrochloride

Trial Locations (1)

14263-0001

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Roswell Park Cancer Institute

OTHER

NCT00053144 - Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter